Furthermore, based on clinical outcomes for the INCAN lung cancer patient cohort, which predominantly received platinum-based therapy (Table II), a multivariate analysis emphasized MEOX2 overexpression as a significant hazard risk, with a significance level of p=0.046 (Table III); these results support the existence of a role for the MEOX2-GLI1 axis in clinical malignancy and/or cancer drug-based therapy resistance versus response, reflected in overall survival. This evidence concerns the gene MEOX2 and lung carcinoma.